Gateway Investment Advisers LLC lessened its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 8.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,930 shares of the biopharmaceutical company’s stock after selling 366 shares during the quarter. Gateway Investment Advisers LLC’s holdings in Incyte were worth $260,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Incyte by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 22,715,821 shares of the biopharmaceutical company’s stock worth $1,294,120,000 after purchasing an additional 196,440 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Incyte by 28.0% during the 2nd quarter. Acadian Asset Management LLC now owns 3,560,989 shares of the biopharmaceutical company’s stock worth $215,833,000 after purchasing an additional 779,243 shares during the period. LSV Asset Management raised its position in shares of Incyte by 0.5% in the 2nd quarter. LSV Asset Management now owns 2,769,892 shares of the biopharmaceutical company’s stock worth $167,911,000 after buying an additional 15,115 shares during the period. Pacer Advisors Inc. raised its position in shares of Incyte by 17,460.4% in the 2nd quarter. Pacer Advisors Inc. now owns 2,692,182 shares of the biopharmaceutical company’s stock worth $163,200,000 after buying an additional 2,676,851 shares during the period. Finally, AQR Capital Management LLC raised its position in shares of Incyte by 70.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,661,758 shares of the biopharmaceutical company’s stock worth $159,905,000 after buying an additional 1,101,041 shares during the period. Hedge funds and other institutional investors own 96.97% of the company’s stock.
Insiders Place Their Bets
In other news, EVP Jonathan Elliott Dickinson sold 8,450 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.36, for a total value of $526,942.00. Following the completion of the transaction, the executive vice president now directly owns 36,390 shares in the company, valued at approximately $2,269,280.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Thomas Tray sold 572 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total transaction of $36,001.68. Following the sale, the insider now owns 24,825 shares in the company, valued at approximately $1,562,485.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jonathan Elliott Dickinson sold 8,450 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $62.36, for a total transaction of $526,942.00. Following the completion of the transaction, the executive vice president now owns 36,390 shares in the company, valued at approximately $2,269,280.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 25,899 shares of company stock worth $1,736,746 over the last quarter. 17.50% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on INCY
Incyte Stock Up 1.1 %
Incyte stock opened at $66.12 on Monday. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. Incyte Co. has a 12-month low of $50.27 and a 12-month high of $70.36. The firm’s fifty day moving average is $64.30 and its 200 day moving average is $60.59. The company has a market capitalization of $14.85 billion, a PE ratio of 20.04, a PEG ratio of 5.30 and a beta of 0.73.
Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). Incyte had a net margin of 2.52% and a return on equity of 0.75%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the firm posted $0.77 EPS. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. As a group, sell-side analysts predict that Incyte Co. will post 0.66 EPS for the current fiscal year.
Incyte Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Read More
- Five stocks we like better than Incyte
- What is a Stock Market Index and How Do You Use Them?
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Using the MarketBeat Stock Split Calculator
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY – Free Report).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.